Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: An NRG Oncology/GOG study
详细信息 查看全文
- 作者：James S. Ferrissa ; James J. Javab ; Michael A. Bookmanc ; Gini F. Flemingd ; Bradley J. Monke ; Joan L. Walkerf ; Howard D. Homesleyg ; Jeffrey Fowlerh ; Benjamin E. Greeri ; Matthew P. Boentej ; Robert A. Burgerk ; burgerr@uphs.upenn.edu" class="auth_mail" title="E-mail the corresponding author
- 关键词：Bevacizumab ; Advanced epithelial ovarian cancer ; Front-line therapy ; NRG Oncology ; GOG
- 刊名：Gynecologic Oncology
- 出版年：2015
- 出版时间：October 2015
- 年：2015
- 卷：139
- 期：1
- 页码：17-22
- 全文大小：401 K
文摘
- •
We analyzed data from GOG 0218 to determine if ascites predicts response to bevacizumab.
- •
Ascites was shown to be a negative prognostic factor in epithelial ovarian cancers.
- •
Ascites is a significant clinical factor that may predict response to bevacizumab.